Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1977
IPSCIO Record ID: 3547
IPSCIO Record ID: 2512
IPSCIO Record ID: 359135
IPSCIO Record ID: 25940
The technology company is about half way through U.S. regulatory testing of its modified silicon product BioSilicon that allows tiny pieces of radioactive material to be directly injected into primary liver tumours, as opposed to traditional radiotherapy that involves hitting a broader area with radiation.
i) interstitially within a cancerous tumour;
ii) into a resection cavity after surgical removal of a cancerous tumour;
iii) into the peritoneal cavity; or
iv) via the vasculature ( to the extent it becomes technically feasible).
IPSCIO Record ID: 4661
IPSCIO Record ID: 5644
Patent Rights means (1) United States Patent No. 4,767,761 (DFCI #111) entitled Ornithine Derivatives and their Use as Methotrexate Resistant Cell Inhibitors
60/376,615, (DFCI #774) entitled Pharmaceutically Active Ornithine Derivatives, Ammonium Salts Thereof and Methods of Making Same.
IPSCIO Record ID: 28677
The License is exclusive with respect to certain patent rights owned by or Licensed to the Licensor.
Neratinib is a tyrosine kinase inhibitor under investigation for the treatment breast cancer and other solid tumors.
IPSCIO Record ID: 299281
University also grants the right to enter into sublicensing agreements under the Patent Rights.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.
KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.
IPSCIO Record ID: 26866
IPSCIO Record ID: 27942
For this purpose, the Company entered into a worldwide exclusive license with the Licensor, through which it obtained the right to combine an antibody that specifically binds to lung adenocarcinoma cells with minimal cross reactivity to other tissues with Company's DOS47â„¢ technology.